Biomarkers of angiogenesis and their role in patient selection for antiangiogenic therapy

Current Angiogenesis

Volumn 1, Issue 2, 2012, Pages 115-124

  Pirie Shepherd, Steven ^a  

^a PFIZER INC   (United States)

Author keywords

Antiangiogenic therapy; Biomarkers; Circulating proteins; DCE MRI; HTS; Platelet proteome

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 2; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CARBOPLATIN; CEDIRANIB; CELL ADHESION MOLECULE; CONTRAST MEDIUM; COVX BODY; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERLEUKIN 8; IRINOTECAN; MOTESANIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACENTAL GROWTH FACTOR; SORAFENIB; STROMAL CELL DERIVED FACTOR 1ALPHA; SUNITINIB; TEMSIROLIMUS; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; BLOOD VESSEL PARAMETERS; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; CONTRAST ENHANCEMENT; DISEASE MARKER; DRUG SAFETY; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; ENDOTHELIUM CELL; GENETIC MARKER; GLIOBLASTOMA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METASTATIC COLORECTAL CANCER; MICROVESSEL DENSITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CARCINOMA; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ADHESION; TUMOR BLOOD FLOW; UPREGULATION; VASODILATATION;

EID: 84899484994     PISSN: 22115528     EISSN: 22115536     Source Type: Journal    
DOI: 10.2174/2211552811201020115     Document Type: Review

References (101)

1. Khleif SN, Doroshow JH, Hait WN; AACR-FDA-NCI Cancer Biomarkers Collaborative. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 2010; 16: 3299-3318.
2. Trusheim MR, Burgess B, Hu SX, et al. Quantifying factors for the success of stratified medicine. Nat Rev Drug Discov 2011; 10: 817-833.
3. Twombly R. Avastin's uncertain future in breast cancer treatment. J Natl Cancer Inst 2011; 103: 458-460.
4. Warren B. The vascular morphology of tumors. In: Peterson H-I, ed. Tumor blood circulation: angiogenesis, vascular morphology and blood flow of experimental and human tumors. Boca Raton, FL: CRC Press; 1979; pp. 1-47.
5. Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor, vasculature. Semin Thromb Hemost 2010; 36: 321-331.
6. Nagy JA, Chang SH, Dvorak AM, Dvorak HF. Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 2009; 100: 865-869.
7. Sitohy B, Nagy JA, Jaminet SC, Dvorak HF. Tumor-Surrogate Blood Vessel, Subtypes Exhibit Differential Susceptibility to Anti-VEGF Therapy. Cancer Res, 2011; 71: 7021-7028.
8. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284: 808-812.
9. Folkman J. Can mosaic tumor vessels facilitate molecular diagnosis of cancer? Proc Natl Acad Sci USA 2001; 98: 98-400.
10. Meehan B, Appu S, St Croix B, Rak-Poznanska K, Klotz L, Rak J. Age-related, properties of the tumour vasculature in renal cell carcinoma. BJU Int 2011; 107: 416-424.
11. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 1998; 102: 430-437.
12. Valadon P, Garnett JD, Testa JE, Bauerle M, Oh P, Schnitzer JE. Screening, phage display libraries for organ-specific vascular immunotargeting in vivo. Proc Natl Acad Sci USA 2006; 103: 407-412.
13. Durr E, Yu J, Krasinska KM, et al. Direct proteomic mapping of the lung microvascular endothelial cell surface invivo and in cell culture. Nat Biotechnol 2004; 22: 985-992.
14. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
15. Launay-Vacher V, Deray G. Hypertension and proteinuria: a classeffect of antiangiogenic therapies. Anticancer Drugs 2009; 20: 81-82.
16. Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K. Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs 2011; 25: 159-169.
17. Bono P, Elfving H, Utriainen T, et al. Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma. Ann Oncol 2009; 20: 393-394.
18. Scartozzi M, Galizia E, Chiorrini S, et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009; 20: 227-230.
19. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010; 11: 1172-1183.
20. Hurwitz H, Douglas PS, Middleton JP, et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV), J Clin Oncol 2010; 28 (suppl): abstr 3039.
21. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96: 189-195.
22. Mendelson DS, Dinolfo M, Cohen RB. First-in-human dose escalation safety and pharmacokinetic (PK) trial of a novel intravenous (IV) thrombospondin-1 (TSP-1) mimetic humanized monoclonal CovX Body (CVX-045) in patients (pts) with advanced solid tumors. J Clin Oncol (Meeting Abstracts) May 2008; 26. (15) suppl 3524.
23. Mendelson DS, Rosen LS, Gordon MS, et al. First-in-human doseescalation safety and PK trial of a novel humanized monoclonal CovX body dual inhibitor of angiopoietin 2 and vascular endothelial growth factor. J Clin Oncol 29: 2011 (suppl) abstr 3055.
24. Machiels JP, Henry S, Zanetta S, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010; 28: 21-28.
25. Leach MO, Brindle KM, Evelhoch JL, et al. Pharmacodynamic/Pharmacokinetic Technologies Advisory Committee, Drug Development Office, Cancer Research UK. The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 2005; 92: 1599-1610.
26. Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol 2008; 1: 20.
27. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24: 769-777.
28. Wong CI, Koh TS, Soo R, et al. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 2009; 27: 4718-4726.
29. Hahn OM, Yang C, Medved M, et al. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 2008; 26: 4572-4578.
30. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003; 21: 3955-3964.
31. Sobrero AF, Bruzzi P. Vatalanib in advanced colorectal cancer: two studies, with identical results. J Clin Oncol 2011; 29(15): 1938-1940.
32. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological, angiogenesis. Annu Rev Pathol 2007; 2: 251-275.
33. Yamazaki Y, Morita T. Molecular and functional diversity of vascular, endothelial growth factors. Mol Divers 2006; 10: 515-527.
34. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
35. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
36. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
37. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. N Engl J Med 2007; 356: 2271-2281.
38. Willett CG, Duda DG, Di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009; 27: 3020-3026.
39. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850.
40. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib, malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26: 1810-1816.
41. Loupakis F, Falcone A, Masi G, et al. Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. J Clin Oncol 2007; 25: 1816-1818.
42. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGFrelated proteins. J Transl Med 2007; 5: 32.
43. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38-47.
44. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007; 104: 17069-17074.
45. Lindauer A, Di Gion P, Kanefendt F, et al. Pharmacokinetic/pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther 2010; 87: 601-608.
46. Zahiragic L, Schliemann C, Bieker R, et al. Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 2007; 21: 1310-1312.
47. Duda DG, Willett CG, Ancukiewicz M, et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 2010; 15: 577-583.
48. Fountzilas G, Kourea HP, Bobos M, et al. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the hellenic cooperative oncology group experience with biological marker evaluation. Anticancer Res 2011; 31: 3007-3018.
49. Horowitz NS, Penson RT, Duda DG, et al. Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig 2011; 4: 26-33.
50. Loupakis F, Cremolini C, Fioravanti A, et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011; 104: 1262-1269.
51. Nikolinakos PG, Altorki N, Yankelevitz D, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res 2010; 70: 2171-2179.
52. Hanrahan EO, Lin HY, Kim ES, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung ancer. J Clin Oncol 2010; 28: 193-201.
53. Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPTTIE2 pathway in malignancy. Nat Rev Cancer 2010; 10: 575-585.
54. Huang H, Lai JY, Do J, et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 2011; 17: 1001-1011.
55. Coxon A, Bready J, Min H, et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther 2010; 9: 2641-2651.
56. Neal J, Wakelee H. AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. Curr Opin Mol Ther 2010; 12: 487-495.
57. Ribatti D. The controversial role of placental growth factor in tumor growth. Cancer Lett 2011; 307: 1-5.
58. Ziche M, Maglione D, Ribatti D, et al. Placenta growth factor-1 is chemotactic, mitogenic and angiogenic. Lab Invest 1999; 176: 517-531.
59. Yonekura H, Sakurai S, Liu X, et al. Yamamoto, Placenta growth factor and vascular endothelial growth factor B and C expression in microvascular endothelial cells and pericytes. Implication in autocrine and paracrine regulation of angiogenesis. J Biol Chem1999; 274: 35172-35178.
60. Hattori K, Heissig B, Wu Y, et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bonemarrow microenvironment. Nat Med 2002; 8: 841-849.
61. Selvaraj SK, Giri RK, Perelman N, Johnson C, Malik P, Kalra VK. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003; 102: 1515-1524.
62. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010; 28: 453-459.
63. Rosen LS, Kurzrock R, Mulay M, et al. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25: 2369-2376.
64. Baar J, Silverman P, Lyons J, et al. A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res 2009; 15: 3583-3590.
65. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008; 14(5): 1407-1412.
66. Byrne GJ, Ghellal A, Iddon J, et al. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J Natl Cancer Inst 2000; 92: 1329-1336.
67. Stopeck AT, Unger JM, Rimsza LM, et al. A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk Lymphoma 2009; 50: 728-735.
68. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-6741.
69. Haura EB, Tanvetyanon T, Chiappori A, et al. Phase, I/II study of the Src inhibitor dasatinib in combination with erlotinib in, advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 1387-1394.
70. Liekens S, Schols D, Hatse S. CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des 2010; 16: 3903-3920.
71. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94: 883-893.
72. Beecken WD, Fernandez A, Joussen AM, et al. Effect of antiangiogenic therapy on slowly growing, poorly vascularized tumors in mice. J Natl Cancer Inst 2001; 93: 382-387.
73. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963-969.
74. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-1393.
75. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011, 10: 417-427.
76. Thomspon EM, Frenkel EP, Neuwelt EA. The paradoxical effect of bevacizumab in the therapy of malignant gliomas. Neurology 2011; 7: 687-693.
77. Dickson PV, Hamner JB, Sims TL, et al. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin Cancer Res 2007; 13: 3942-3950.
78. Sorensen AG, Emblem KE, Polaskova P, et al. Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion. Cancer Res 2012; 72: 402-407.
79. Mancuso P, Bertolini F. Circulating endothelial cells as biomarkers in clinical oncology. Microvasc Res 2010; 79: 224-228.
80. Rafat N, Beck GC, Schulte J, Tuettenberg J, Vajkoczy P. Circulating endothelial progenitor cells in malignant gliomas. J Neurosurg 2010; 112: 43-49.
81. Matsusaka S, Mishima Y, Suenaga M, et al. Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab. Cancer 2011; 117: 4026-4032.
82. Bertolini F, Marighetti P, Shaked Y. Cellular and soluble markers of tumor angiogenesis: from patient selection to the identification of the most appropriate postresistance therapy. Biochim Biophys Acta 2010; 1806: 131-137.
83. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006; 6: 835-845.
84. Monestiroli S, Mancuso P, Burlini A, et al. Kinetics and viability of circulating endothelialcells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001; 6: 4341-4344.
85. Goon PK, Lip GY, Stonelake PS, Blann AD. Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial, damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham, Prognostic Index. Neoplasia 2009; 1: 771-779.
86. Rabascio C, Muratori E, Mancuso P, et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res 2004; 64: 4373-4377.
87. Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelialcell, kinetics and viability predict survival in breast cancer patients receiving, metronomic chemotherapy. Blood 2006; 108: 452-459.
88. Norden-Zfoni A, Desai J, Manola J, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; 13: 2643-2650.
89. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039-2049.
90. Lyden D, Hattori K, Dias S, et al. Impaired recruitment of bonemarrow-derived endothelial and hematopoietic precursor cells blocks tumor, angiogenesis and growth. Nat Med 2001; 7: 1194-1201.
91. Gao D, Mittal V. The role of bone-marrow-derived cells in tumor growth, metastasis initiation and progression. Trends Mol Med 2009; 15: 333-343.
92. Schneider BP, Radovich M, Sledge GW, et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 2008; 111: 157-163.
93. Krippl P, Langsenlehner U, Renner W, et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003; 106: 468-471.
94. Steffensen KD, Waldstrøm M, Brandslund I, Jakobsen A. The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. Gynecol Oncol 2010; 117: 109-116.
95. Koutras A, Antonacopoulou A, Fostira F, et al. Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab in the first-line setting. J Clin Oncol 2010; 27 Abstract 3587.
96. Schneider BP, Wang M, Radovich M, et al; ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26: 4672-4678.
97. Lambrechts D, Delmar P, Buysschaert I, et al. VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumabtreated patients with metastatic pancreatic cancer. Joint ECCOESMO Multidisciplinary Congress; 2009 Sep 20-24; Berlin, Germany. Abstract No. 16LBA.
98. Kisucka J, Butterfield CE, Duda DG, et al. Platelets and platelet adhesion, support angiogenesis while preventing excessive hemorrhage. Proc Natl Acad Sci USA 2006; 103: 855-860.
99. Pietramaggiori G, Scherer SS, Cervi D, Klement G, Orgill DP. Tumors stimulate platelet delivery of angiogenic factors in vivo: an unexpected benefit. Am J Pathol 2008; 173: 1609-1616.
100. Klement GL, Yip TT, Cassiola F, et al. Platelets, actively sequester angiogenesis regulators. Blood 2009; 113: 2835-2842.
101. Peterson JE, Zurakowski D, Italiano JE Jr, et al. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 2010; 85: 487-493.